PUBLISHER: Lucintel | PRODUCT CODE: 1386202
PUBLISHER: Lucintel | PRODUCT CODE: 1386202
The future of the global diphtheria vaccine market looks promising with opportunities in the hospital, clinic, and vaccination center markets. The global diphtheria vaccine market is expected to reach an estimated $7.5 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are increasing demand for combination vaccines, rising awareness of the importance of diphtheria vaccination, and growing government initiatives to promote diphtheria vaccination programs.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global diphtheria vaccine by vaccine type, end use, and region.
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies diphtheria vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diphtheria vaccine companies profiled in this report include-
Lucintel forecasts that DTaP vaccine will remain the largest segment due to its wide usage to protects against diphtheria, tetanus, and pertussis.
Within this market, hospital will remain the largest segment as it's a common places where people get vaccinated against diphtheria.
North America is expected to witness highest growth over the forecast period due to rising cases of diphtheria among unvaccinated people and presence of key manufacturers in the region.
Market Size Estimates: Diphtheria vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Diphtheria vaccine market size by vaccine type, end use, and region in terms of value ($B).
Regional Analysis: Diphtheria vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different vaccine types, end uses, and regions for the diphtheria vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the diphtheria vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Answer: The global diphtheria vaccine market is expected to reach an estimated $7.5 billion by 2030.
Answer: The global diphtheria vaccine market is expected to grow with a CAGR of 6.5% from 2024 to 2030.
Answer: The major drivers for this market are increasing demand for combination vaccines, rising awareness of the importance of diphtheria vaccination, and growing government initiatives to promote diphtheria vaccination programs.
Answer: The future of the diphtheria vaccine market looks promising with opportunities in the hospital, clinic, and vaccination center markets.
Answer: Some of the key diphtheria vaccine companies are as follows:
Answer: Lucintel forecasts that DTaP vaccine will remain the largest segment due to its wide usage to protects against diphtheria, tetanus, and pertussis.
Answer: North America is expected to witness highest growth over the forecast period due to rising cases of diphtheria among unvaccinated people and presence of key manufacturers in the region.
Answer: Yes, Lucintel provides 10% customization without any additional cost.